These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30653670)

  • 1. Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations.
    Wang Y; Zhu H; Madabushi R; Liu Q; Huang SM; Zineh I
    Clin Pharmacol Ther; 2019 Apr; 105(4):899-911. PubMed ID: 30653670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on Fit-For-Purpose Models for Regulatory Applications.
    Wang Y; Huang SM
    J Pharm Sci; 2019 Jan; 108(1):18-20. PubMed ID: 30244011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
    Galluppi GR; Ahamadi M; Bhattacharya S; Budha N; Gheyas F; Li CC; Chen Y; Dosne AG; Kristensen NR; Magee M; Samtani MN; Sinha V; Taskar K; Upreti VV; Yang J; Cook J
    Clin Pharmacol Ther; 2024 Aug; 116(2):282-288. PubMed ID: 38519861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.
    Wu YE; Zheng YY; Li QY; Yao BF; Cao J; Liu HX; Hao GX; van den Anker J; Zheng Y; Zhao W
    Adv Drug Deliv Rev; 2024 Aug; 211():115364. PubMed ID: 38936664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):799-809. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.
    Al-Huniti N; Feng Y; Yu JJ; Lu Z; Nagase M; Zhou D; Sheng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):419-427. PubMed ID: 32589767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective.
    Pan X; Wang L; Liu J; Earp JC; Yang Y; Yu J; Li F; Bi Y; Bhattaram A; Zhu H
    J Clin Pharmacol; 2023 Nov; 63 Suppl 2():S65-S77. PubMed ID: 37942906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.
    O'Donnell JC; Le TK; Dobrin R; Higashi M; Pereira A; Wagner S; Yang A; Hukkelhoven M
    Future Oncol; 2021 Jan; 17(3):333-347. PubMed ID: 33074018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An AI Approach to Generating MIDD Assets Across the Drug Development Continuum.
    Barrett JS; Goyal RK; Gobburu J; Baran S; Varshney J
    AAPS J; 2023 Jul; 25(4):70. PubMed ID: 37430126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?
    Eichler HG; Bloechl-Daum B; Broich K; Kyrle PA; Oderkirk J; Rasi G; Santos Ivo R; Schuurman A; Senderovitz T; Slawomirski L; Wenzl M; Paris V
    Clin Pharmacol Ther; 2019 Apr; 105(4):912-922. PubMed ID: 30178490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.